Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
1400 participants
OBSERVATIONAL
2019-02-11
2049-02-11
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Follow-up of Patients With Multiple Myeloma in the West-Occitanie Region "Living With a Myeloma in West-Occitanie"
NCT04888039
Genomic and Phenotypic Determinants of Resistance to Immunotherapies in Multiple Myeloma
NCT03848676
A Study of Real Life Treatment for Multiple Myeloma (MM)
NCT04985643
Vulnerability and Therapeutic Changes in Older Patients With Multiple Myeloma.
NCT02063113
Clinical Outcomes and Prognostic Factors in Multiple Myeloma Patients
NCT06457464
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MYRACLE patients
Prélèvement sanguin (2*4mL) ou médullaire (2mL)
Additional blood (2\*4mL) or bone marrow (2mL) sample depending on clinical presentation of disease
Data collection through questionnaires
Collection of quality of life and occupational exposure data via questionnaires
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Prélèvement sanguin (2*4mL) ou médullaire (2mL)
Additional blood (2\*4mL) or bone marrow (2mL) sample depending on clinical presentation of disease
Data collection through questionnaires
Collection of quality of life and occupational exposure data via questionnaires
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient having consented to participate in the study and his/her biocollection
* Patient affiliated to or benefiting from a social security scheme or similar
Exclusion Criteria
* Major under guardianship or curatorship
* Protected persons.
* Pregnant or breast-feeding women
* Persons benefiting from the AME
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nantes University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Cyrille TOUZEAU, PU
Role: PRINCIPAL_INVESTIGATOR
Nantes University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
La Roche sur Yon Hospital Departmental
La Roche-sur-Yon, , France
Nantes University Hospital
Nantes, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Derrien J, Gastineau S, Frigout A, Giordano N, Cherkaoui M, Gaborit V, Boinon R, Douillard E, Devic M, Magrangeas F, Moreau P, Minvielle S, Touzeau C, Letouze E. Acquired resistance to a GPRC5D-directed T-cell engager in multiple myeloma is mediated by genetic or epigenetic target inactivation. Nat Cancer. 2023 Nov;4(11):1536-1543. doi: 10.1038/s43018-023-00625-9. Epub 2023 Aug 31.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IDRCB - ANSM
Identifier Type: OTHER
Identifier Source: secondary_id
RC18_0197
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.